Abstract
Small molecules are powerful pharmacological tools to dissect biological events. There is now considerable interest in expanding efforts to identify and use small molecules targeting proteins encoded in the genomes of humans and pathogenic organisms. Integration of the principles of molecular pharmacology with contemporary high-throughput and high-content screening technologies is essential for the success of these discovery activities. We present some of the challenges and opportunities provided by the Molecular Library Screening Centers Network (MLSCN), which is a National Institutes of Health Roadmap Initiative.
Footnotes
-
This work supported in part by National Institutes of Health Grants 5U54-HG003918 (R.D.) and 5U54-MH074411 (J.S.L.).
-
ABBREVIATIONS: DMSO, dimethyl sulfoxide; HEK, human embryonic kidney; HTS, high-throughput screening; MLSCN, Molecular Library Screening Centers Network; OED, Oxford English Dictionary; TR-FRET, time-resolved fluorescence resonance energy transfer; MLSMR, Molecular Libraries Small Molecule Repository.
- Received February 11, 2007.
- Accepted March 29, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
